Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Head and Neck Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Penile Neoplasms 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Neoplasm Metastasis 1Melanoma 1Colonic Neoplasms 1Castration Resistant Prostate Cancer 1Carcinoma, Renal Cell 1Breast Neoplasms 1Anus Neoplasms 1

Interventions

Gemcitabine 54Specimen Handling 16Fluorouracil 15Radiotherapy 13Biopsy 12Oxaliplatin 10Magnetic Resonance Spectroscopy 10Erlotinib Hydrochloride 10Cyclophosphamide 10aldesleukin 8fludarabine 7Bevacizumab 7sargramostim 6Radiation 6veliparib 5Trastuzumab 5Leucovorin 5Cetuximab 5Capecitabine 5Taxes 4Sunitinib 4Irinotecan 4HhAntag691 4Cisplatin 42,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 4tipifarnib 3rubitecan 3entinostat 3X-Rays 3Sorafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Pancreatic Neoplasms × bintrafusp alfa protein, human × Clear all
NCT04327986 2022-05-18

Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
3 enrolled 13 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡